Aims and Scope
Cancer Chemotherapy and Pharmacology is a peer-reviewed medical journal covering oncological pharmacotherapy. It was established in 1978 and is published by Springer Science+Business Media. The editors-in-chief are E.Chatelut (Paul Sabatier University) and E.A. Sausville (University of Maryland). It has been included in Index medicus (MEDLINE) since its first issue. According to the ISI 2016 Journal Citation Reports, the journal has an impact factor of 2.737, and its ranking was 98/254 (Pharmacology & Pharmacy) and 122/217 (Oncology).
Key Metrics
5.9
CiteScore
CiteScore
CiteScore measures average citations received per document published in the serial.
< 5
Impact Factor
Impact Factor
Impact factor of a journal is calculated by dividing the number of current year citations to the source items published in that journal during the previous two years.
0.88
5-Year SI
5-year SI
- N/A 2-year SI
- 0.87 Lifetime SI
Scite Index
Scite Index
scite Index is the ratio of citations supporting research which is published in the journal to sum of citations either supporting or contrasting the research published in the journal for the same time period. Minimum 100 supporting citations required.
Q2
Oncology
SJR
- Q2 Oncology
- Q2 Toxicology
- Q2 Pharmacology
- Q2 Cancer Research
- Q1 Pharmacology (medical)
SJR
SJR
SCImago Journal Rank measures weighted citations received by the serial. Citation weighting depends on subject field and prestige (SJR) of the citing serial.
0.96
SNIP
SNIP
Source Normalized Impact per Paper measures actual citations received relative to citations expected for the serial’s subject field.
4 Mo
Time to Publish
Time to Publish
Based on turnaround time from submission to publication for papers (articles & reviews) published in 2022 and for journals with a sample of more than 10 papers.
Time To Publish
Time to Publish
Based on turnaround time from submission to publication for papers (articles & reviews) published in 2022 and for journals with a sample of more than 10 papers.
Time to Publish
Based on turnaround time from submission to publication for papers (articles & reviews) published in 2022 and for journals with a sample of more than 10 papers.
% of papers by time taken from submission to publication
0 to 3 months
25%
4 to 6 months
60%
7 to 9 months
12%
Above 9 months
2%
Did you find this useful?
Thank you for your feedback.
Topics Covered
- Chemotherapy
- Cancer
- Lipid metabolism
- Lung cancer
- DNA repair
- Methotrexate
- Oral administration
- Hepatocellular carcinoma
- Bioavailability
- Breast cancer
- Toxicity
- Irinotecan
- Initial dose
- Epidermal growth factor receptor
- Crizotinib
- Mitochondrial targeting
- Overall survival
- Renal function
- Cisplatin
- Diarrhea
Journal Specifications
| Overview | |
| Publisher | SPRINGER |
| Language | English |
| Frequency | Monthly |
| General Details | |
| Language | English |
| Frequency | Monthly |
| Publication Start Year | 1978 |
| Publisher URL | Visit website |
| Website URL | Visit website |
Planning to publish in Cancer Chemotherapy and Pharmacology ?
Upload your Manuscript to get
- Degree of match
- Common matching concepts
- Additional journal recommendations
Looking for the right journals to submit your mansucript?
Upload your manuscript and get a submission readiness score and other journal recommendations.
Check my PaperRecently Published Papers
-
Full paper
Successful desensitization in a patient with metastatic colorectal cancer presenting with regorafenib-mediated fix drug eruption.
- 19 Oct 24
- Cancer chemotherapy and pharmacology
-
Full paper
An intracerebral microdialysis study to determine the neuropharmacokinetics of eribulin in patients with metastatic or primary brain tumors.
- 18 Oct 24
- Cancer chemotherapy and pharmacology
-
Full paper
Retraction Note: NO donor inhibits proliferation and induces apoptosis by targeting PI3K/AKT/mTOR and MEK/ERK pathways in hepatocellular carcinoma cells.
- 16 Oct 24
- Cancer chemotherapy and pharmacology
-
Full paper
A comparison of the renal function biomarkers serum creatinine, pro-enkephalin and cystatin C to predict clearance of pemetrexed.
- 4 Oct 24
- Cancer chemotherapy and pharmacology
-
Full paper
Ferroptosis - a potential feature underlying neratinib-induced colonic epithelial injury.
- 1 Oct 24
- Cancer chemotherapy and pharmacology
-
Full paper
Avermectin B1 mediates antitumor activity and induces autophagy in osteosarcoma through the AMPK/ULK1 signaling pathway.
- 1 Oct 24
- Cancer chemotherapy and pharmacology
Scite analysis
Powered by scite_
9.6k articles received 158.2k citations see all
- 7,122 Supporting
- 147,535 Mentioning
- 979 Contrasting
Editorial notices
- 14 Retractions
- 0 Withdrawals
- 45 Corrections
- 50 Errata
- 1 Expression of Concern
FAQs
How long has Cancer Chemotherapy and Pharmacology been actively publishing?
Cancer Chemotherapy and Pharmacology has been in operation since 1978 till date.
What is the publishing frequency of Cancer Chemotherapy and Pharmacology ?
Cancer Chemotherapy and Pharmacology published with a Monthly frequency.
How many articles did Cancer Chemotherapy and Pharmacology publish last years ?
In 2023, Cancer Chemotherapy and Pharmacology published 126 articles.
What is the eISSN & pISSN for Cancer Chemotherapy and Pharmacology ?
For Cancer Chemotherapy and Pharmacology,eISSN is 1432-0843 and pISSN is0344-5704.
What is Citescore for Cancer Chemotherapy and Pharmacology ?
Citescore for Cancer Chemotherapy and Pharmacology is 5.9.
What is SNIP score for Cancer Chemotherapy and Pharmacology ?
SNIP score for Cancer Chemotherapy and Pharmacology is 0.96.
What is the SJR for Cancer Chemotherapy and Pharmacology ?
SJR for Cancer Chemotherapy and Pharmacology is Q2.
Who is the publisher of Cancer Chemotherapy and Pharmacology ?
SPRINGER is the publisher of Cancer Chemotherapy and Pharmacology.